-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56

Benzinga·07/31/2026 10:15:13
语音播报
Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.